Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Acacia Pharma Group

OTCPK:ACPG.F
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ACPG.F
OTCPK
€149M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Acacia Pharma Group plc, a hospital pharmaceutical company, focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients in the United States and internationally. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • Acacia Pharma Group has significant price volatility in the past 3 months.
ACPG.F Share Price and Events
7 Day Returns
0%
OTCPK:ACPG.F
3.1%
US Pharmaceuticals
-2.6%
US Market
1 Year Returns
-
OTCPK:ACPG.F
-3.4%
US Pharmaceuticals
-13.3%
US Market
ACPG.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Acacia Pharma Group (ACPG.F) 0% 0.3% 41.2% - - -
US Pharmaceuticals 3.1% -4.8% -8.7% -3.4% 8.9% 4.8%
US Market -2.6% -15.2% -22.2% -13.3% 5.7% 17.2%
1 Year Return vs Industry and Market
  • No trading data on ACPG.F.
  • No trading data on ACPG.F.
Price Volatility
ACPG.F
Industry
5yr Volatility vs Market

Value

 Is Acacia Pharma Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Acacia Pharma Group. This is due to cash flow or dividend data being unavailable. The share price is $3.46.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Acacia Pharma Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Acacia Pharma Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:ACPG.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.43
ENXTBR:ACPH Share Price ** ENXTBR (2020-03-17) in EUR €2.33
ENXTBR:ACPH Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.081 $2.52
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.1x
United States of America Market PE Ratio Median Figure of 2,946 Publicly-Listed Companies 12.49x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Acacia Pharma Group.

OTCPK:ACPG.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:ACPH Share Price ÷ EPS (both in USD)

= 2.52 ÷ -0.43

-5.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Acacia Pharma Group is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Acacia Pharma Group is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Acacia Pharma Group's expected growth come at a high price?
Raw Data
OTCPK:ACPG.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-36%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.89x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Acacia Pharma Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Acacia Pharma Group's assets?
Raw Data
OTCPK:ACPG.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.08
ENXTBR:ACPH Share Price * ENXTBR (2020-03-17) in EUR €2.33
ENXTBR:ACPH Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.081 $2.52
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.29x
United States of America Market PB Ratio Median Figure of 5,158 Publicly-Listed Companies 1.22x
OTCPK:ACPG.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:ACPH Share Price ÷ Book Value per Share (both in USD)

= 2.52 ÷ 0.08

31.81x

* Primary Listing of Acacia Pharma Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Acacia Pharma Group is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Acacia Pharma Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Acacia Pharma Group has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Acacia Pharma Group expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-36%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Acacia Pharma Group expected to grow at an attractive rate?
  • Unable to compare Acacia Pharma Group's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Acacia Pharma Group's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Acacia Pharma Group's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:ACPG.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:ACPG.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -36%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:ACPG.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:ACPG.F Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 37 -51 1
2020-12-31 3 -44 1
OTCPK:ACPG.F Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -20 -23
2019-09-30 -25 -26
2019-06-30 -23 -25
2019-03-31 -19 -23
2018-12-31 -15 -21
2018-09-30 -9 -16
2018-06-30 -9 -12
2018-03-31 -7 -11
2017-12-31 -5 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Acacia Pharma Group is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Acacia Pharma Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:ACPG.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Acacia Pharma Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:ACPG.F Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.74 -0.74 -0.74 1.00
2020-12-31 -0.62 -0.62 -0.62 1.00
OTCPK:ACPG.F Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.43
2019-09-30 -0.50
2019-06-30 -0.47
2019-03-31 -0.47
2018-12-31 -0.47
2018-09-30 -0.50
2018-06-30 -0.65
2018-03-31 -0.99
2017-12-31 -3.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Acacia Pharma Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Acacia Pharma Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Acacia Pharma Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Acacia Pharma Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Acacia Pharma Group's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Acacia Pharma Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Acacia Pharma Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Acacia Pharma Group's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Acacia Pharma Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Acacia Pharma Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:ACPG.F Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -22.84 18.47 3.93
2019-09-30 -26.40 21.12 5.52
2019-06-30 -25.06 21.50 5.85
2019-03-31 -22.88 18.26 5.43
2018-12-31 -20.69 15.02 5.03
2018-09-30 -15.67 9.37 3.55
2018-06-30 -12.32 4.24 2.66
2018-03-31 -10.64 3.23 2.41
2017-12-31 -8.34 2.07 2.00
2016-12-31 -16.66 1.03 16.80
2015-12-31 -18.99 3.52 14.86
2015-09-30 -11.62 1.04 12.64
2015-06-30 -10.11 1.07 10.42
2015-03-31 -8.83 1.00 9.06
2014-12-31 -8.50 1.03 8.68
2013-12-31 -12.54 0.49 9.98

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Acacia Pharma Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Acacia Pharma Group has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Acacia Pharma Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Acacia Pharma Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Acacia Pharma Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Acacia Pharma Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Acacia Pharma Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Acacia Pharma Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Acacia Pharma Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Acacia Pharma Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Acacia Pharma Group Company Filings, last reported 3 months ago.

OTCPK:ACPG.F Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 4.35 9.77 17.01
2019-09-30 4.35 9.77 17.01
2019-06-30 12.15 9.53 22.73
2019-03-31 12.15 9.53 22.73
2018-12-31 24.67 9.32 37.44
2018-09-30 31.74 9.64 44.07
2018-06-30 34.85 9.36 47.12
2018-03-31 37.07 9.95 50.13
2017-12-31 -24.04 27.51 4.15
2016-12-31 -14.49 16.33 8.50
2015-12-31 -4.12 6.32 8.05
2015-09-30 10.16 0.00 8.23
2015-06-30 -6.18 8.68 2.30
2015-03-31 -5.84 8.20 2.18
2014-12-31 -3.39 7.58 4.11
2013-12-31 -3.19 7.03 5.61
  • Acacia Pharma Group's level of debt (224.6%) compared to net worth is high (greater than 40%).
  • Acacia Pharma Group had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Acacia Pharma Group has less than a year of cash runway based on current free cash flow.
  • Acacia Pharma Group has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.7% each year.
X
Financial health checks
We assess Acacia Pharma Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Acacia Pharma Group has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Acacia Pharma Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Acacia Pharma Group dividends. Estimated to be 0% next year.
If you bought $2,000 of Acacia Pharma Group shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Acacia Pharma Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Acacia Pharma Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:ACPG.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:ACPG.F Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Acacia Pharma Group has not reported any payouts.
  • Unable to verify if Acacia Pharma Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Acacia Pharma Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Acacia Pharma Group has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Acacia Pharma Group's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Acacia Pharma Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Acacia Pharma Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Acacia Pharma Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Acacia Pharma Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Bolinder
COMPENSATION $171,800
TENURE AS CEO 0.7 years
CEO Bio

Mr. Michael Bolinder, also known as Mike, has been Chief Executive Officer at Acacia Pharma Group plc since August 1, 2019 and its Director since August 2019. He served as the Chief Commercial Officer of Acacia Pharma Inc at Acacia Pharma Group plc until August, 2019. Mr. Bolinder joined Acacia Pharma in August 2015 as Vice President of Marketing. He has experience in the pharmaceutical industry. Prior to Acacia Pharma, he served as the Head of Marketing and Commercial Strategy for the Hospital Division at Mallinckrodt Pharmaceuticals (via the Cadence Pharmaceuticals, Inc. acquisition) which commercialised Ofirmev®, a post-operative pain control product promoted to anaesthetists and surgical teams. Prior to joining Cadence Pharmaceuticals, Inc., he worked at Eli Lilly and Company for years in various sales and marketing roles of increasing responsibility across multiple therapeutic areas and successful product launches. He earned his bachelor’s degree from Florida State University with double majors of International Business and Spanish.

CEO Compensation
  • Insufficient data for Mike to compare compensation growth.
  • Mike's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Acacia Pharma Group management team in years:

0.2
Average Tenure
  • The average tenure for the Acacia Pharma Group management team is less than 2 years, this suggests a new team.
Management Team

Mike Bolinder

TITLE
CEO & Director
COMPENSATION
$172K
TENURE
0.7 yrs

Gary Gemignani

TITLE
Chief Financial Officer
AGE
54
TENURE
0.2 yrs

Gabriel Fox

TITLE
Chief Medical Officer
COMPENSATION
$555K

Ian Walker

TITLE
Head of Project Leadership

Anne-Marie Elsley

TITLE
Company Secretary
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure and age of the Acacia Pharma Group board of directors in years:

2.1
Average Tenure
57
Average Age
  • The average tenure for the Acacia Pharma Group board of directors is less than 3 years, this suggests a new board.
Board of Directors

Patrick Vink

TITLE
Independent Non-Executive Chairman
COMPENSATION
$117K
AGE
56
TENURE
4.3 yrs

Mike Bolinder

TITLE
CEO & Director
COMPENSATION
$172K
TENURE
0.7 yrs

John Brown

TITLE
Senior Independent Director
COMPENSATION
$51K
AGE
64
TENURE
2.1 yrs

Ed Borkowski

TITLE
Independent Non-Executive Director
COMPENSATION
$48K
AGE
61
TENURE
2.1 yrs

Pieter van der Meer

TITLE
Non-Executive Director

Johan Kördel

TITLE
Non-Executive Director
AGE
57

Scott Byrd

TITLE
Non-Executive Director
COMPENSATION
$43K
AGE
49
TENURE
5.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Acacia Pharma Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Acacia Pharma Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Acacia Pharma Group plc, a hospital pharmaceutical company, focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients in the United States and internationally. The company’s lead product is BAREMSIS, an intravenous formulation of amisulpride that has completed Phase III clinical trials for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also comprise APD403 that has completed Phase II clinical trials for the chemotherapy-induced nausea and vomiting treatment. The company was founded in 2007 and is based in Cambridge, the United Kingdom.

Details
Name: Acacia Pharma Group plc
ACPG.F
Exchange: OTCPK
Founded: 2007
€161,565,140
64,119,865
Website: http://www.acaciapharma.com
Address: Acacia Pharma Group plc
The Officers’ Mess,
Royston Road,
Cambridge,
Cambridgeshire, CB22 4QH,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR ACPH Ordinary Shares Euronext Brussels BE EUR 05. Mar 2018
OTCPK ACPG.F Ordinary Shares Pink Sheets LLC US USD 05. Mar 2018
LSE 0PNT Ordinary Shares London Stock Exchange GB EUR 05. Mar 2018
Number of employees
Current staff
Staff numbers
33
Acacia Pharma Group employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 03:47
End of day share price update: 2020/03/17 00:00
Last estimates confirmation: 2020/03/05
Last earnings filing: 2020/03/03
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.